| Literature DB >> 32033158 |
Marek Kazimierczyk1, Marta K Kasprowicz1, Marta E Kasprzyk1, Jan Wrzesinski1.
Abstract
The application of a new generation of sequencing techniques has revealed that most of the genome has already been transcribed. However, only a small part of the genome codes proteins. The rest of the genome "dark matter" belongs to divergent groups of non-coding RNA (ncRNA), that is not translated into proteins. There are two groups of ncRNAs, which include small and long non-coding RNAs (sncRNA and lncRNA respectively). Over the last decade, there has been an increased interest in lncRNAs and their interaction with cellular components. In this review, we presented the newest information about the human lncRNA interactome. The term lncRNA interactome refers to cellular biomolecules, such as nucleic acids, proteins, and peptides that interact with lncRNA. The lncRNA interactome was characterized in the last decade, however, understanding what role the biomolecules associated with lncRNA play and the nature of these interactions will allow us to better understand lncRNA's biological functions in the cell. We also describe a set of methods currently used for the detection of lncRNA interactome components and the analysis of their interactions. We think that such a holistic and integrated analysis of the lncRNA interactome will help to better understand its potential role in the development of organisms and cancers.Entities:
Keywords: detection lncRNA interactome; lncRNA; lncRNA interactome; lncRNA interactome function; long noncoding RNA
Mesh:
Substances:
Year: 2020 PMID: 32033158 PMCID: PMC7037361 DOI: 10.3390/ijms21031027
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Human long non-coding RNAs (lncRNA) interactome, interaction of human lncRNA with cellular biomolecules.
Examples of pathogenesis related to lncRNA dysregulation.
| Disease | LncRNA | Impact on Pathogenesis | Mechanism |
|---|---|---|---|
| Colon cancer | DACOR1 [ | Downregulated in colon tumors | Interacts with and inhibits DNA methyltransferase DNMT1 |
| Lung cancer | HOTAIR [ | Impacts proliferation, survival, invasion, metastasis, and drug resistance in lung cancer cells | HOTAIR may promote dedifferentiation of lung epithelial cells through two distinct mechanisms, i.e., transcriptional repression of |
| Prostate cancer | LINCRNA-p21 [ | Decreases prostate cancer cell proliferation | LINCRNA-p21 inhibits many genes expression in a p53-dependent transcriptional response |
| Parkinson’s disease | H19, LincRNA-p21, MALAT1, and SNHG1 [ | H19 is significantly downregulated in Parkinson’s disease while LincRNA-p21, Malat1 and SNHG1, are significantly upregulated. | Associated with synaptogenesis, proliferation, apoptosis, precedes Parkinson’s disease |
| Leukemia | MALAT1 [ | Inhibiting multiple myeloma growth | Involved in multiple myeloma DNA repair and cell death. |
| Cardiovascular diseases | GAS5 [ | Promotes the development and progression of myocardial infarctions | Targeting of the miR-525-5p/CALM2 axis |
| Diabetes | HI-LNC901, PLUTO [ | Implicated in pancreatic islet function | Regulates the transcription of |
| AIDS | LINC00173 [ | Regulates cytokines in T cells | Presumably involved in transcriptional regulation |
Selected lncRNAs interacting with microRNA (miRNA) and their functions.
| LncRNA | Interacting miRNA | Function in the Cell | |
|---|---|---|---|
|
| LINC-ROR | miR-138, miR-145, miR-204 [ | competing endogenous RNAs |
| LNCRNA-KRTAP5-AS1, LNCRNA-TUBB2A | specific miRNA [ | ||
| CASC2 | miR-21, miR-18a [ | ||
| CDR1AS/CIRS-7 | miR-671, miR-7 [ | ||
| LINC-MD1 | miR-133, miR-135 [ | ||
| MDRL | miR-361 [ | ||
| HULC | miR-372 [ | ||
| LINC-223 | miR-125-5p [ | ||
| LNCARSR | mir-34, miR-449 [ | ||
| LNCND | miR-143-3p [ | ||
| UFC1 | miR-34a [ | cell cycle | |
| LINC00152 | miR-138 [ | ||
| MALAT1 | miR-101, miR-217, miR-9, miR-125b [ | controlling proliferation and senescence | |
| UCA1 | miR-1 [ | ||
| BACE1-AS | mir-485-5p [ | modulation of mRNA stability | |
| H19 | miR-106a, miR-17-5p, miR-20b, let-7 [ | transcriptional regulation | |
| HOTAIR | miR-34a, miRNA-141, miR-130a, miRNA-let7 [ | ||
| MEG3 | miRNA-29 [ | ||
| GAS5 | miR-21 [ | ||
| HOST2 | let-7b [ | ||
| PCAT-1 | miR-3667-3p [ | post-transcriptional regulation | |
| LINCRNA-P21 | let-7 [ | modulation of translation |
Some examples of lncRNA–mRNA pairing.
|
|
|
|
|
| SAF | FAS [ | alternative splicing | |
| ZEB NAT | ZEB [ | ||
| MALAT | CAMK2B, CDK7, SAT1, HMG2L1, ARHGEF1, B- MYB [ | ||
| PCA3 | PRUNE [ | A–I mRNA editing | |
| LAST | CCDI [ | mRNA stability | |
| BACE1 | BACE1 [ | ||
| LINCRNA p21 | JUNB, CTNNB1 [ |
Examples of lncRNA interacting with DNA and their postulated function.
|
|
|
|
|
| AIR | Slc22a3 promoter [ | Epigenetic control of gene expression | |
| FENDRR | Foxf1, Pitx2 promoters [ | ||
| TUNA | Nanog, Sox2 and Fgf4 promoters [ | ||
| MEG3 | TGF-β pathway genes [ | ||
| PARTICLE | Upstream of MATSA promoter [ | ||
| NEAT1 | Multiple binding sites [ | Paraspecle formation | |
| MALAT1 | Multiple binding sites [ | Alternative splicing regulation, promotes metastasis | |
| LncRNA DHFR | DHFR promoter [ | Transcription regulation | |
| TERRA | Telomers [ | Telomer replication control |
lncRNA-protein complexes involved in the regulation of cellular functions.
|
|
|
|
|
|
| KCNP1ot1 | 91.7 kb | PRC1, PRC2, G9a [ | Epigenetic control of gene expression | |
| XIST | 19 kb | PRC2, hnRNP U, YY1 [ | ||
| AIR | 4.3 kb | G9a [ | ||
| ANRIL | 3.8 kb | PRC1 [ | ||
| HOTTIP | 3.8 kb | WDR5, MLL [ | ||
| HOTAIR | 2.4 kb | PRC2, LSD1/CoREST/REST [ | ||
| H19 | 2.3 kb | PRC2 [ | ||
| DEANR1 | 4.9 kb | SMAD2/3 [ | Transcription regulation | |
| LINCRNA-p21 | 2.7 kb | HnRNP [ | ||
| PANDA | 1.5 kb | SAFA [ | ||
| GAS5 | 1.0 kp | GR (NR3C1) [ | ||
| LNC-DC | 630 bp | STAT-3 [ | ||
| 7SK | 330 bp | P-TEFb [ | ||
| MIAT (Gomafu) | 10 kb | SF1 [ | Alternative splicing | |
| MALAT (NEAT2) | 8.7 kb | SR [ | ||
| PNKY | 1.6 kb | hnRNP [ | ||
| BC1 | 152 bp | EIF4A/eIF4B, PABP [ | Translation regulation | |
| THRIL | 2.9 kb | HnRNP [ | Immune response |